Back to Stakeholders
EmpathBio, Inc.
Data updated
1 Trial
EmpathBio Inc. is an ATAI Life Sciences subsidiary developing EMP-01, an MDMA derivative designed to preserve entactogenic therapeutic properties while reducing cardiovascular and stimulant side effects, with PTSD as the primary indication. The company completed a Phase 1 trial of EMP-01 in 32 healthy volunteers in New Zealand.
Academic Research
0 papersPublished Papers
0
Trial Involvement
1
Distinct Focus Topics
0
Latest Publication
Unknown
Corporate lineage
Parent companies and acquirers above, entities absorbed or acquired below.
active
active
EmpathBio, Inc.
This organisationResearch journey
EmpathBio, Inc. works on MDMA. Here is where that compound’s research stands.
Quick Facts
- Type
- Subsidiary
- HQ
- United States
- Parent
- AtaiBeckley
- Website
- Archived copy
Live site unavailable; links to a Wayback Machine snapshot.